Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21
Phase 31

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT04799275Phase 2/3Active Not Recruiting
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma+18 more
PrincipalinvestigatorStart date: 2021-05-20

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Reem Karmali, MD

Northwestern University

Related
4 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+4 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Ryan Lynch

Fred Hutch/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedGrade 3b Follicular Lymphoma+3 more
Similarity Score9%

Mengyang Di, MD, PhD

Fred Hutch/University of Washington Cancer Consortium

Related
4 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+2 more
Similarity Score7%

Elias Jabbour, MD

M.D. Anderson Cancer Center

Related
15 trials

Shared therapeutic areas:

High Grade B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Joseph M Tuscano

University of California, Davis

Related
5 trials

Shared therapeutic areas:

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Ariela Noy, MD

Memorial Sloan Kettering Cancer Center

Related
6 trials

Shared therapeutic areas:

Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Beth Christian, MD

Ohio State University Comprehensive Cancer Center

Related
2 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise Specified
Similarity Score3%

Ajay Gopal

Fred Hutch/University of Washington Cancer Consortium

Related
8 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Luke Walker, MD

Umoja Biopharma

Related
3 trials

Shared therapeutic areas:

Grade 3b Follicular Lymphoma
Similarity Score1%

Steven P. Treon, MD, MA, PhD

Dana-Farber Cancer Institute

Related
4 trials

Shared therapeutic areas:

Lymphoplasmacytic Lymphoma
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT04799275Phase 2/3PrincipalInvestigator

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma+18 more
Active Not Recruiting

All 1 trials loaded